TLN-372 in Advanced KRAS Mutant Solid Tumors
ConditionKRAS Mutant Solid Tumors
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorTreeline Biosciences, Inc.
About this trial
The primary purpose of this study is to evaluate the safety, pharmacokinetics, and anti-tumor activity of TLN-372 as a single agent and in combination with other anti-tumor agents, in patients with advanced KRAS mutant solid tumors
Eligibility criteria
Qualifiers
Patients must have measurable disease at study entry.
Patients must have locally advanced or metastatic KRAS mutant solid tumors.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Adequate organ function.
Disqualifiers
Patients must not have active brain metastases.
Patients must not have current or past history of central nervous system (CNS) involvement.
Patients must not have major surgery or severe trauma within 4 weeks prior to the start of the study.
Patients must not have any condition, including significant acute or chronic medical illness, active or uncontrolled infection, or the presence of laboratory abnormalities, that places patients at unacceptable risk of participating in this study.
Trial design
Treatments tested in this trial
- TLN-372
- TLN-372 in combination with cetuximab
- TLN-372 in combination with pembrolizumab
Treatment groups
240 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov